These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 66972)

  • 1. Combination chemotherapy of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, dacarbazine and vinblastine (ABDV).
    Case DC; Young CW; Lee BJ
    Cancer; 1977 Apr; 39(4):1382-6. PubMed ID: 66972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of advanced Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) after failure of MOPP therapy.
    Krikorian JG; Portlock CS; Rosenberg SA
    Cancer; 1978 Jun; 41(6):2107-11. PubMed ID: 77716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
    J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New multiple-agent chemotherapy (B-DOPA) for advanced Hodgkin's disease.
    Lokich JJ; Frei E; Jaffe N; Tullis J
    Cancer; 1976 Aug; 38(2):667-71. PubMed ID: 61797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The treatment of advanced hodgkin's disease.
    Straus DJ; Lee BJ; Koziner B; Nisce LZ; Young CW; Clarkson BD
    Blut; 1981 Aug; 43(2):119-24. PubMed ID: 6167303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD).
    Santoro A; Bonadonna G
    Cancer Chemother Pharmacol; 1979; 2(2):101-5. PubMed ID: 93984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
    Piga A; Ambrosetti A; Todeschini G; Cetto G; Perona G; Cellerino R
    Cancer Treat Rep; 1984; 68(7-8):947-51. PubMed ID: 6204754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eight-drug combination chemotherapy (MOPP and ABDV) and local radiotherapy for advanced Hodgkin's Disease.
    Case DC; Young CW; Nisce L; Lee BJ; Clarkson BD
    Cancer Treat Rep; 1976 Sep; 60(9):1217-23. PubMed ID: 65221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Post-MOPP chemotherapy of Hodgkin's disease (author's transl)].
    Osieka R; Bruntsch U; Gallmeier WM; Seeber S; Schmidt CG
    Dtsch Med Wochenschr; 1976 Aug; 101(32):1177-82. PubMed ID: 59661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP.
    Santoro A; Viviani S; Villarreal CJ; Bonfante V; Delfino A; Valagussa P; Bonadonna G
    Cancer Treat Rep; 1986 Mar; 70(3):343-8. PubMed ID: 2420444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Successful chemotherapy of cancer. Remission of Hodgkin's disease. IV].
    Lopez M
    Clin Ter; 2001; 152(3):203-6. PubMed ID: 11692542
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP.
    Bonadonna G; Zucali R; Monfardini S; De Lena M; Uslenghi C
    Cancer; 1975 Jul; 36(1):252-9. PubMed ID: 54209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease.
    Santoro A; Viviani S; Valagussa P; Bonfante V; Bonadonna G
    Semin Oncol; 1986 Mar; 13(1 Suppl 1):23-6. PubMed ID: 2420012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined chemotherapy (MOPP or ABVD)-radiotherapy approach in advanced Hodgkin's disease.
    Bonadonna G; Zucali R; De Lena M; Valagussa P
    Cancer Treat Rep; 1977 Aug; 61(5):769-77. PubMed ID: 70270
    [No Abstract]   [Full Text] [Related]  

  • 15. Pediatric Hodgkin's disease.
    Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
    J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages?
    Andrieu JM; Colonna P
    J Clin Oncol; 1998 Jun; 16(6):2283. PubMed ID: 9626234
    [No Abstract]   [Full Text] [Related]  

  • 18. Third-line salvage chemotherapy in Hodgkin's disease.
    Bonadonna G; Viviani S; Valagussa P; Bonfante V; Santoro A
    Semin Oncol; 1985 Mar; 12(1 Suppl 2):23-5. PubMed ID: 2579440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of MOPP-refractory Hodgkin's disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine.
    Einhorn LH; Williams SD; Stevens EE; Bond WH; Chenoweth L
    Cancer; 1983 Apr; 51(8):1348-52. PubMed ID: 6186356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced Hodgkin's disease: ABVD is better, yet is not good enough!
    Diehl V
    J Clin Oncol; 2003 Feb; 21(4):583-5. PubMed ID: 12586791
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.